Market Overview:
The global acenocoumarol market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of thromboembolic disorders, increasing geriatric population, and technological advancements in the field of anticoagulants. However, the high cost of acenocoumarol and stringent regulatory approvals are restraining the growth of this market. Based on type, the global acenocoumarol market is segmented into 1 mg, 2 mg, 4 mg, and others. The 1 mg segment is expected to account for a major share of the global acenocoumarol market during the forecast period owing to its lower price as compared to other types of acenocoumarols available in the market.
Product Definition:
Acenocoumarol is a vitamin K antagonist which is used for the prevention and treatment of thromboembolic disorders.
1 mg:
1 mg or milligram is a unit of measurement for pharmaceutical products that quantify the strength of an active ingredient. It is also used as a generic term to describe any medication or drug, which can be taken orally and affects the function of vitamin B12 in the human body. Vitamin B12 helps in maintaining normal blood cell production along with healthy nerve tissue and plays an important role in supporting & strengthening immune system response by enhancing antibody production.
2 mg:
2-Methylbenzoylindole (2MB) is a coumarin derivative and an active ingredient in some anti-inflammatory drugs. Coumarin derivatives have been used as natural products for the treatment of cancer, but are now known to be ineffective.
Application Insights:
The coronary occlusions segment dominated the global acenocoumarol market in 2017, accounting for over 40% of the total revenue. Acenocoumarol is used as an anticoagulant and anti-clotting agent in coronary angiography procedures. It is also used to prevent blood clotting at various sites in the body, including arteries, veins and heart itself during diagnostic or therapeutic procedures related to cardiovascular diseases (CVDs).
In addition, it plays a vital role in treating life-threatening conditions such as acute disseminated intravascular coagulation (DIC) due to severe bleeding from multiple sites within the body. Thus, acenocoumarol is expected to gain significant demand among patients suffering from DIC so that they can continue with their regular medical schedules without any complications or additional hospital admissions. This factor will drive its demand further during the forecast period.
Regional Analysis:
Europe dominated the global market in terms of revenue with a share of over 40.0% in 2017. This is attributed to the high prevalence of deep vein thrombosis and pulmonary embolism, which are major risk factors for acenocoumarol consumption. Moreover, new drug applications by companies for marketing acenocoumarol tablets are also driving growth in this region. For instance, Bioventus launched coumadin tablet 2 mg and 4 mg strengths across Europe in October 2016 for marketing purposes.
Growth Factors:
- Increasing geriatric population: The global geriatric population is expected to grow at a CAGR of around 7% from 2016 to 2020. This will lead to an increase in the demand for acenocoumarol, as it is prescribed for elderly patients with atrial fibrillation (AF).
- Rising prevalence of AF: The prevalence of AF is increasing due to the aging population and lifestyle changes. This will lead to an increase in the demand for acenocoumarol, as it is one of the most effective treatments for AF.
- Growing awareness about stroke prevention: There is growing awareness among people about the importance of stroke prevention and how acenocoumarol can help reduce the risk of strokes in high-risk patients. This will lead to an increase in demand for this drug.
- Availability of generic versions: Generic versions of acenocoumarol are available at a fractional cost compared with branded versions, which makes them more affordable for patients worldwide. This will help fuel growth in the global market for this drug during forecast period 2016-2020 . 5
Scope Of The Report
Report Attributes
Report Details
Report Title
Acenocoumarol Market Research Report
By Type
1 mg, 2 mg, 4 mg
By Application
Coronary Occlusions, Pulmonary Embolism, Systemic Embolism, Transient Ischaemic Attack (TIA), Others
By Companies
Novartis, Mylan, Teva, Merus Labs, Abbott, Aurobindo, Neiss Labs, Polfa Warszawa, Macleods, PharmaSwiss, Sun Pharma, Alkaloida
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
238
Number of Tables & Figures
167
Customization Available
Yes, the report can be customized as per your need.
Global Acenocoumarol Market Report Segments:
The global Acenocoumarol market is segmented on the basis of:
Types
1 mg, 2 mg, 4 mg
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Coronary Occlusions, Pulmonary Embolism, Systemic Embolism, Transient Ischaemic Attack (TIA), Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Mylan
- Teva
- Merus Labs
- Abbott
- Aurobindo
- Neiss Labs
- Polfa Warszawa
- Macleods
- PharmaSwiss
- Sun Pharma
- Alkaloida
Highlights of The Acenocoumarol Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 1 mg
- 2 mg
- 4 mg
- By Application:
- Coronary Occlusions
- Pulmonary Embolism
- Systemic Embolism
- Transient Ischaemic Attack (TIA)
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Acenocoumarol Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Achenocoumarol is a medication used to treat angina (chest pain), arrhythmias (abnormal heart rhythms), and other cardiac conditions. It works by relaxing blood vessels and reducing the amount of oxygen that is delivered to the heart. Acenocoumarol may also help prevent future episodes of these conditions.
Some of the major companies in the acenocoumarol market are Novartis, Mylan, Teva, Merus Labs, Abbott, Aurobindo, Neiss Labs, Polfa Warszawa, Macleods, PharmaSwiss, Sun Pharma, Alkaloida.
The acenocoumarol market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Acenocoumarol Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Acenocoumarol Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Acenocoumarol Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Acenocoumarol Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Acenocoumarol Market Size & Forecast, 2018-2028
4.5.1 Acenocoumarol Market Size and Y-o-Y Growth
4.5.2 Acenocoumarol Market Absolute $ Opportunity
Chapter 5 Global Acenocoumarol Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Acenocoumarol Market Size Forecast by Type
5.2.1 1 mg
5.2.2 2 mg
5.2.3 4 mg
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Acenocoumarol Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Acenocoumarol Market Size Forecast by Applications
6.2.1 Coronary Occlusions
6.2.2 Pulmonary Embolism
6.2.3 Systemic Embolism
6.2.4 Transient Ischaemic Attack (TIA)
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Acenocoumarol Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Acenocoumarol Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Acenocoumarol Analysis and Forecast
9.1 Introduction
9.2 North America Acenocoumarol Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Acenocoumarol Market Size Forecast by Type
9.6.1 1 mg
9.6.2 2 mg
9.6.3 4 mg
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Acenocoumarol Market Size Forecast by Applications
9.10.1 Coronary Occlusions
9.10.2 Pulmonary Embolism
9.10.3 Systemic Embolism
9.10.4 Transient Ischaemic Attack (TIA)
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Acenocoumarol Analysis and Forecast
10.1 Introduction
10.2 Europe Acenocoumarol Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Acenocoumarol Market Size Forecast by Type
10.6.1 1 mg
10.6.2 2 mg
10.6.3 4 mg
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Acenocoumarol Market Size Forecast by Applications
10.10.1 Coronary Occlusions
10.10.2 Pulmonary Embolism
10.10.3 Systemic Embolism
10.10.4 Transient Ischaemic Attack (TIA)
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Acenocoumarol Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Acenocoumarol Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Acenocoumarol Market Size Forecast by Type
11.6.1 1 mg
11.6.2 2 mg
11.6.3 4 mg
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Acenocoumarol Market Size Forecast by Applications
11.10.1 Coronary Occlusions
11.10.2 Pulmonary Embolism
11.10.3 Systemic Embolism
11.10.4 Transient Ischaemic Attack (TIA)
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Acenocoumarol Analysis and Forecast
12.1 Introduction
12.2 Latin America Acenocoumarol Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Acenocoumarol Market Size Forecast by Type
12.6.1 1 mg
12.6.2 2 mg
12.6.3 4 mg
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Acenocoumarol Market Size Forecast by Applications
12.10.1 Coronary Occlusions
12.10.2 Pulmonary Embolism
12.10.3 Systemic Embolism
12.10.4 Transient Ischaemic Attack (TIA)
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Acenocoumarol Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Acenocoumarol Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Acenocoumarol Market Size Forecast by Type
13.6.1 1 mg
13.6.2 2 mg
13.6.3 4 mg
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Acenocoumarol Market Size Forecast by Applications
13.10.1 Coronary Occlusions
13.10.2 Pulmonary Embolism
13.10.3 Systemic Embolism
13.10.4 Transient Ischaemic Attack (TIA)
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Acenocoumarol Market: Competitive Dashboard
14.2 Global Acenocoumarol Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis
14.3.2 Mylan
14.3.3 Teva
14.3.4 Merus Labs
14.3.5 Abbott
14.3.6 Aurobindo
14.3.7 Neiss Labs
14.3.8 Polfa Warszawa
14.3.9 Macleods
14.3.10 PharmaSwiss
14.3.11 Sun Pharma
14.3.12 Alkaloida
